Faculty Advisor

Adams, David S.

Abstract

Medulloblastoma (MB) patients suffer a poor prognosis and limitations of current treatments necessitate development of targeted therapies. TRAIL, a pro-apoptotic protein, targets tumor cells while sparing normal cells; however some tumors remain resistant, including the MB cell line DAOY. Mesenchymal stem cells (MSC) have been used for their tumoritropic properties to deliver apoptotic proteins. In this study, a TRAIL-expressing MSC line was investigated for a therapeutic effect on DAOYs in vitro, in the presence or absence of HDAC inhibitor MS-275. Results indicate that DAOYs respond to secreted TRAIL, and that MS-275 enhances this effect. Bioluminescent imaging shows that DAOYs survive and grow in an intracranial xenograft mouse model, allowing for future in vivo studies.

Publisher

Worcester Polytechnic Institute

Date Accepted

January 2011

Major

Biology and Biotechnology

Project Type

Major Qualifying Project

Accessibility

Unrestricted

Advisor Department

Biology and Biotechnology

Share

COinS